BR0207716A - Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos - Google Patents
Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferosInfo
- Publication number
- BR0207716A BR0207716A BR0207716-7A BR0207716A BR0207716A BR 0207716 A BR0207716 A BR 0207716A BR 0207716 A BR0207716 A BR 0207716A BR 0207716 A BR0207716 A BR 0207716A
- Authority
- BR
- Brazil
- Prior art keywords
- mammals
- compound
- pharmaceutical formulation
- serotonin uptake
- inhibiting norepinephrine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27373001P | 2001-03-06 | 2001-03-06 | |
| PCT/US2002/003385 WO2002070457A1 (en) | 2001-03-06 | 2002-02-20 | Inhibitor of monoamine uptake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207716A true BR0207716A (pt) | 2004-03-23 |
Family
ID=23045157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207716-7A BR0207716A (pt) | 2001-03-06 | 2002-02-20 | Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20040082666A1 (https=) |
| EP (1) | EP1379492B1 (https=) |
| JP (1) | JP2004525912A (https=) |
| KR (1) | KR20030092012A (https=) |
| CN (1) | CN1229331C (https=) |
| AP (1) | AP2003002855A0 (https=) |
| AT (2) | AT414238B (https=) |
| AU (1) | AU2002245385B2 (https=) |
| BR (1) | BR0207716A (https=) |
| CA (1) | CA2440161A1 (https=) |
| CH (1) | CH695982A5 (https=) |
| CZ (1) | CZ20032380A3 (https=) |
| DE (1) | DE60226715D1 (https=) |
| DK (1) | DK200301267A (https=) |
| EA (1) | EA005768B1 (https=) |
| EC (1) | ECSP034760A (https=) |
| EE (1) | EE200300419A (https=) |
| ES (2) | ES2201942B2 (https=) |
| FI (1) | FI20031191L (https=) |
| GB (1) | GB2389851B (https=) |
| HR (1) | HRP20030710A2 (https=) |
| HU (1) | HUP0303341A3 (https=) |
| IL (1) | IL157779A0 (https=) |
| LT (1) | LT5143B (https=) |
| LU (1) | LU91038B1 (https=) |
| LV (1) | LV13119B (https=) |
| NO (1) | NO20033921L (https=) |
| NZ (1) | NZ527431A (https=) |
| OA (1) | OA12494A (https=) |
| PL (1) | PL363840A1 (https=) |
| SE (1) | SE526598C2 (https=) |
| SK (1) | SK10632003A3 (https=) |
| TR (1) | TR200705146T1 (https=) |
| WO (1) | WO2002070457A1 (https=) |
| ZA (1) | ZA200306882B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH695982A5 (de) * | 2001-03-06 | 2006-11-15 | Lilly Co Eli | Inhibitor der Monaminaufnahme. |
| CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| EP1729754B1 (en) * | 2003-12-12 | 2008-07-02 | Eli Lilly And Company | Selective norepinephrine reuptake inhibitors for the treatment of hot flashes |
| WO2011027359A2 (en) * | 2009-07-30 | 2011-03-10 | Matrix Laboratories Ltd | Novel process for the preparation of 4-hydroxy atomoxetine |
| WO2012020418A1 (en) | 2010-08-12 | 2012-02-16 | Matrix Laboratories Ltd | Novel polymorphs of 4-hydroxy atomoxetine hydrochloride |
| DE102013022397A1 (de) | 2013-12-19 | 2016-07-07 | Metrax Gmbh | Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage |
| GR1008819B (el) | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου |
| CN107935848B (zh) * | 2017-11-21 | 2020-12-22 | 中国农业科学院兰州畜牧与兽药研究所 | 一种六茜素衍生物及其制备方法和应用 |
| WO2020091862A1 (en) * | 2018-10-31 | 2020-05-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4194009A (en) | 1974-01-10 | 1980-03-18 | Eli Lilly And Company | Aryloxyphenylpropylamines for obtaining a psychotropic effect |
| US4018895A (en) | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
| US5112619A (en) * | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| CA1327795C (en) * | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
| PH30083A (en) * | 1991-02-25 | 1996-12-27 | Lilly Co Eli | Treatment of lower urinary tract disorders |
| TW514634B (en) | 1997-10-14 | 2002-12-21 | Lilly Co Eli | Process to make chiral compounds |
| AU3219800A (en) | 1999-03-29 | 2000-10-16 | Eli Lilly And Company | Stereospecific method for preparing tomoxetine and intermediates thereof |
| CA2362185C (en) | 1999-04-09 | 2009-06-02 | Eli Lilly And Company | Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof |
| BR0115301A (pt) * | 2000-11-15 | 2004-12-14 | Lilly Co Eli | Uso de um inibidor seletivo da recaptação de norepinefrina |
| CH695982A5 (de) * | 2001-03-06 | 2006-11-15 | Lilly Co Eli | Inhibitor der Monaminaufnahme. |
-
2002
- 2002-02-20 CH CH01522/03A patent/CH695982A5/de not_active IP Right Cessation
- 2002-02-20 GB GB0323169A patent/GB2389851B/en not_active Expired - Fee Related
- 2002-02-20 EA EA200300978A patent/EA005768B1/ru not_active IP Right Cessation
- 2002-02-20 CN CNB028060253A patent/CN1229331C/zh not_active Ceased
- 2002-02-20 PL PL02363840A patent/PL363840A1/xx not_active Application Discontinuation
- 2002-02-20 SK SK1063-2003A patent/SK10632003A3/sk unknown
- 2002-02-20 HR HR20030710A patent/HRP20030710A2/hr not_active Application Discontinuation
- 2002-02-20 AP APAP/P/2003/002855A patent/AP2003002855A0/en unknown
- 2002-02-20 LU LU91038A patent/LU91038B1/fr active
- 2002-02-20 WO PCT/US2002/003385 patent/WO2002070457A1/en not_active Ceased
- 2002-02-20 ES ES200350052A patent/ES2201942B2/es not_active Expired - Fee Related
- 2002-02-20 BR BR0207716-7A patent/BR0207716A/pt not_active IP Right Cessation
- 2002-02-20 FI FI20031191A patent/FI20031191L/fi not_active IP Right Cessation
- 2002-02-20 EP EP02713538A patent/EP1379492B1/en not_active Revoked
- 2002-02-20 ES ES02713538T patent/ES2305221T3/es not_active Expired - Lifetime
- 2002-02-20 CA CA002440161A patent/CA2440161A1/en not_active Abandoned
- 2002-02-20 NZ NZ527431A patent/NZ527431A/en unknown
- 2002-02-20 AU AU2002245385A patent/AU2002245385B2/en not_active Ceased
- 2002-02-20 US US10/468,553 patent/US20040082666A1/en not_active Abandoned
- 2002-02-20 IL IL15777902A patent/IL157779A0/xx unknown
- 2002-02-20 AT AT0904202A patent/AT414238B/de not_active IP Right Cessation
- 2002-02-20 OA OA1200300215A patent/OA12494A/en unknown
- 2002-02-20 AT AT02713538T patent/ATE396170T1/de not_active IP Right Cessation
- 2002-02-20 EE EEP200300419A patent/EE200300419A/xx unknown
- 2002-02-20 KR KR10-2003-7011635A patent/KR20030092012A/ko not_active Ceased
- 2002-02-20 HU HU0303341A patent/HUP0303341A3/hu unknown
- 2002-02-20 JP JP2002569778A patent/JP2004525912A/ja not_active Ceased
- 2002-02-20 DE DE60226715T patent/DE60226715D1/de not_active Revoked
- 2002-02-20 CZ CZ20032380A patent/CZ20032380A3/cs unknown
- 2002-02-20 TR TR2007/05146T patent/TR200705146T1/xx unknown
-
2003
- 2003-08-11 LT LT2003075A patent/LT5143B/lt unknown
- 2003-09-02 EC EC2003004760A patent/ECSP034760A/es unknown
- 2003-09-03 SE SE0302361A patent/SE526598C2/sv not_active IP Right Cessation
- 2003-09-03 ZA ZA200306882A patent/ZA200306882B/en unknown
- 2003-09-04 DK DK200301267A patent/DK200301267A/da not_active Application Discontinuation
- 2003-09-04 NO NO20033921A patent/NO20033921L/no not_active Application Discontinuation
- 2003-09-10 LV LVP-03-100A patent/LV13119B/en unknown
-
2005
- 2005-05-09 US US11/125,348 patent/US7384983B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| BRPI0212733B8 (pt) | composição farmacêutica compreendendo composto inibidor da recaptação de serotonina, e, uso do mesmo | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| BRPI0410630A (pt) | antagonista de nk1 | |
| BR0112292A (pt) | Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto | |
| BRPI0413124A (pt) | método e equipamento para melhorar desempenho | |
| EA200401169A1 (ru) | Аминометилзамещенные тетрациклиновые соединения | |
| BR0115482A (pt) | Composição de sacralose melhorada e processo para sua preparação | |
| BR0115427A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto | |
| BR0316535A (pt) | Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina | |
| MY117971A (en) | Denaturants for sympathomimetic amine salts | |
| DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| BR0215027A (pt) | Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| PT1250340E (pt) | Metodos e compostos para inibicao de mrp1 | |
| BR0207716A (pt) | Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos | |
| TW200508195A (en) | 3-aminopyrrolidines as inhibitors of monoamine uptake | |
| NO20043124L (no) | Aminoindanderivater som serotonin -og norepinefrin-opptaksinhibitorer | |
| WO2004052858A3 (en) | Inhibitors of monoamine uptake | |
| IS6087A (is) | N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka | |
| ATE389405T1 (de) | Fexofenadine hydrochlorid polymorph | |
| WO2004078180A3 (en) | Naaladase inhibitors for treating opioid tolerance | |
| BRPI0408453A (pt) | composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo | |
| BR0208593A (pt) | método para o tratamento de um mamìfero, composto, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010. |